Our Mission

Our mission is to pioneer the next wave of modern medicines to treat and cure the most significant diseases facing mankind today.

Learn more about Abpro →

Although mankind has made dramatic advances in fighting disease to date, some of the deadliest afflictions remain uncured, including cancer and autoimmune disorders. Since its inception, the biotechnology industry has played a major role in developing new therapies. Even though the first wave of therapies has been effective, a new era of modern medicine is now emerging. Recent discoveries have provided insights into how we can better utilize the immune system to fight disease the way nature intended, and new advances in bioengineering have provided ways to leverage the immune system to our advantage. We believe understanding the complex interactions between molecules and cells will provide the key to the next generation of breakthrough therapies. The world of treatment possibilities abounds with this knowledge and we are positioned to translate these findings into new medicines to better the human condition.


Our fully owned and partnered programs are differentiated by a consistent focus on first-in-class or best-in-class targets across multiple indications where our product candidates have strong potential.


Mar 21, 2017

Abpro Expands Senior Leadership Team and Announces Appointment of Gavin MacBeath, Ph.D. as Chief Scientific Officer

Read more →

Feb 2, 2017

Abpro Expands Senior Leadership Team and Announces Adam Mostafa as Chief Financial Officer

Read more →

Nov 29, 2016

Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody

Read more →


Come join us! We offer a fast-paced, dynamic, team-based environment with opportunities to learn and grow with the company.